Gilead Sciences (GILD) Tops Q3 EPS by 94c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Gilead Sciences Announces Third Quarter 2021 Financial Results
October 28, 2021 4:02 PM EDT2 Million Patients Received Veklury (remdesivir) or Licensed Generic Remdesivir in the Third Quarter
Biktarvy Sales Increased 20% Year-Over-Year to Record $2.3 Billion
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter 2021.
This was a very strong third quarter with continued positive momentum for both our commercial performance and our pipeline progress, said Daniel ODay, Chairman and Chief Executive Officer, Gilead Sciences. Veklury is making a significant impact as the COVID-19 pandemic continues... More
